- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: HEMERA-1: Safety Study of PP-007 in Subjects With Acute Ischemic Stroke (clinicaltrials.gov) - May 24, 2024
P1, N=24, Recruiting,
Completed --> Recruiting | N=16 --> 24 | Trial completion date: Mar 2023 --> Feb 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial completion date, Trial primary completion date: HEMERA-1: Safety Study of PP-007 in Subjects With Acute Ischemic Stroke (clinicaltrials.gov) - Jul 28, 2023
P1, N=16, Completed,
Completed --> Recruiting | N=16 --> 24 | Trial completion date: Mar 2023 --> Feb 2025 | Trial primary completion date: Dec 2022 --> Dec 2024 Trial completion date: Sep 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Dec 2022
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Review, Journal: Hemoglobin-Based Oxygen Carriers: Where Are We Now in 2023? (Pubmed Central) - Mar 2, 2023
OxyVita and Sanguinate are still undergoing active clinical studies. The field of oxygen therapeutics seems to be entering a phase of rapid growth in the coming 10-20 years.
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Review, Journal: Promising Cerebral Blood Flow Enhancers in Acute Ischemic Stroke. (Pubmed Central) - Nov 18, 2022
We identified heme-free soluble guanylate cyclase activators; Sanguinate, remote ischemic perconditioning; Fasudil, S1P agonists; and stimulation of the sphenopalatine ganglion as promising potential CBF-enhancing therapeutics requiring further investigation. Additionally, we outline and discuss the critical steps required to advance research strategies for clinically translatable CBF-enhancing agents in the context of acute ischemic stroke models.
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial completion: HEMERA-1: Safety Study of PP-007 in Subjects With Acute Ischemic Stroke (clinicaltrials.gov) - Oct 4, 2022
P1, N=16, Completed,
Additionally, we outline and discuss the critical steps required to advance research strategies for clinically translatable CBF-enhancing agents in the context of acute ischemic stroke models. Recruiting --> Completed
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Journal: Recruitment of monocytes primed to express heme oxygenase-1 ameliorates pathological lung inflammation in cystic fibrosis. (Pubmed Central) - Jun 9, 2022
Finally, we show that PP-007 does not compromise the clearance of PA in the setting of chronic airway infection. Overall, we reveal the mechanism of action of PP-007 responsible for the immunomodulatory function observed in clinical trials for a wide range of diseases and demonstrate the potential use of PP-007 in controlling neutrophilic pulmonary inflammation by promoting the expression of HO-1 in monocytes/macrophages.
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Journal: Tangential Flow Filtration Facilitated Fractionation and PEGylation of Low and High Molecular Weight Polymerized Hemoglobins and Their Biophysical Properties. (Pubmed Central) - Mar 1, 2022
Several commercial PEGylated Hbs (MP4®, Sanguinate®, Euro-PEG-Hb) have been developed for clinical use with a longer circulatory half-life and improved safety compared to Hb...Both T- and R-state PEG-PolybHb exhibited significantly lower haptoglobin binding rates than the precursor PolybHb, indicating potentially reduced clearance by CD163+ monocytes and macrophages. Thus, PEG-PolybHb is expected to function as a promising HBOC due to its low oxygen affinity and enhanced stealth properties afforded by the PEG hydration shell.
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Enrollment open, Trial completion date, Trial primary completion date: HEMERA-1: Safety Study of PP-007 in Subjects With Acute Ischemic Stroke (clinicaltrials.gov) - Feb 8, 2022
P1, N=16, Recruiting,
Thus, PEG-PolybHb is expected to function as a promising HBOC due to its low oxygen affinity and enhanced stealth properties afforded by the PEG hydration shell. Not yet recruiting --> Recruiting | Trial completion date: Oct 2021 --> Dec 2022 | Trial primary completion date: Aug 2021 --> Sep 2022
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Clinical, Review, Journal: Early Experiences With PEGylated Carboxyhemoglobin Bovine in Anemic Jehovah's Witnesses: A Case Series and Review of the Literature. (Pubmed Central) - Apr 27, 2021
We report 3 cases in which the HBOC, PEGylated carboxyhemoglobin bovine (Sanguinate®), was requested under emergent circumstances for severely anemic (hemoglobin <5 g/dL) JW patients who refused blood transfusions...The other patient's hemoglobin recovered and she was discharged in stable condition. This series demonstrates the complex nature of the critically anemic JW population and highlights the clinical considerations of using HBOCs in clinical practice and the critical need for further research before they can be broadly recommended.
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial initiation date: HEMERA-1: Safety Study of PP-007 in Subjects With Acute Ischemic Stroke (clinicaltrials.gov) - Feb 23, 2021
P1, N=16, Not yet recruiting,
These promising findings warrant further development and investigation of PC as a low-volume, early treatment for hemorrhagic shock in scenarios where blood products may not be available. Initiation date: Dec 2020 --> Mar 2021
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharmaceuticals
[VIRTUAL] Surgical Pearls for Graft and Suture Technique () - Oct 23, 2020 - Abstract #ASDS2020ASDS_266;
The sanguinated surgical defect/wound bed is covered by a 4”x4” woven gauze sponge...The running horizontal mattress with alternating simple running loops technique offers all of the benefits of the vertical mattress sutures without the difficulty of removal. Simplifying the suture removal process improves patient’s comfort and minimizes the suture removal encounter time.
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharmaceuticals
Journal: Alternatives to Transfusion. (Pubmed Central) - May 7, 2020
http://creativecommons.org/licenses/by-nc-nd/4. We find that artificial oxygen carriers are an attractive field of research because of the practical limitations and the multitude of potential complications that surround human blood transfusions.
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharmaceuticals
Journal: Pharmacotherapy in Acutely Anemic Jehovah's Witnesses: An Evidence-Based Review. (Pubmed Central) - Sep 28, 2019
There are currently not enough data to make definitive recommendations on the use of pharmacological agents to treat severe anemia in the JW population. Further evidence utilizing EPO and HBOCs will be beneficial to guide therapy.
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Enrollment change, Trial withdrawal: Safety and Pharmacokinetics of SANGUINATE (clinicaltrials.gov) - Jun 2, 2018
P1, N=0, Withdrawn,
Clinical studies (likely with repeat dosing) are required to evaluate whether this effect can prevent DCI or cerebral infarction. N=15 --> 0 | Suspended --> Withdrawn
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial completion, Trial completion date: Study of SANGUINATE (clinicaltrials.gov) - May 30, 2018
P2, N=24, Completed,
N=15 --> 0 | Suspended --> Withdrawn Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> Dec 2017
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: A Study on SANGUINATE (clinicaltrials.gov) - May 30, 2018
P2, N=0, Withdrawn,
Active, not recruiting --> Completed | N=10 --> 5 N=60 --> 0 | Trial completion date: Apr 2017 --> Dec 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2016 --> Oct 2018
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial completion, Trial completion date, Trial primary completion date: A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients (clinicaltrials.gov) - May 30, 2018
P2, N=34, Completed,
N=60 --> 0 | Trial completion date: Apr 2017 --> Dec 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2016 --> Oct 2018 Active, not recruiting --> Completed | Trial completion date: May 2018 --> May 2017 | Trial primary completion date: Dec 2017 --> May 2017
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Enrollment closed, Trial completion date, Trial primary completion date: A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients (clinicaltrials.gov) - Apr 18, 2018
P2, N=30, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: May 2018 --> May 2017 | Trial primary completion date: Dec 2017 --> May 2017 Recruiting --> Active, not recruiting | Trial completion date: Sep 2017 --> May 2018 | Trial primary completion date: Jul 2017 --> Dec 2017
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Enrollment closed: Study of SANGUINATE (clinicaltrials.gov) - Dec 13, 2017
P2, N=24, Active, not recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Sep 2017 --> May 2018 | Trial primary completion date: Jul 2017 --> Dec 2017 Recruiting --> Active, not recruiting
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial completion, Trial primary completion date: A Phase 1 Safety Study of SANGUINATE (clinicaltrials.gov) - May 18, 2017
P1, N=102, Completed,
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Dec 2017 --> May 2017
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Phase classification, Enrollment change, Trial primary completion date: A Phase 1 Safety Study of SANGUINATE (clinicaltrials.gov) - Mar 27, 2017
P1, N=100, Recruiting,
Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Aug 2016 Phase classification: P1/2 --> P1 | N=10 --> 100 | Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial completion, Trial initiation date: SANGUINATE (clinicaltrials.gov) - Feb 27, 2017
P2, N=10, Completed,
Phase classification: P1/2 --> P1 | N=10 --> 100 | Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Completed | Initiation date: Jan 2015 --> Mar 2016
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial initiation date, Trial primary completion date: Study of SANGUINATE (clinicaltrials.gov) - Nov 30, 2016
P2, N=24, Recruiting,
Not yet recruiting --> Completed | Initiation date: Jan 2015 --> Mar 2016 Initiation date: Jun 2015 --> Nov 2016 | Trial primary completion date: Dec 2016 --> Sep 2017
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial completion: Safety and Effect of SANGUINATE (clinicaltrials.gov) - Oct 27, 2016
P2, N=12, Completed,
Initiation date: Jun 2015 --> Nov 2016 | Trial primary completion date: Dec 2016 --> Sep 2017 Recruiting --> Completed
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial completion: Efficacy and Safety of SANGUINATE (clinicaltrials.gov) - Oct 27, 2016
P2/3, N=60, Completed,
Recruiting --> Completed Recruiting --> Completed
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Enrollment open: A Phase 1 Safety Study of SANGUINATE (clinicaltrials.gov) - Jun 16, 2016
P1/2, N=10, Recruiting,
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial primary completion date: Study of SANGUINATE (clinicaltrials.gov) - Jun 15, 2016
P2, N=24, Recruiting,
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2016 --> Dec 2016
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial initiation date: SANGUINATE (clinicaltrials.gov) - May 2, 2016
P2, N=10, Not yet recruiting,
Trial primary completion date: Apr 2016 --> Dec 2016 Initiation date: Jan 2016 --> Jan 2015
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
New P1/2 trial: A Phase 1 Safety Study of SANGUINATE (clinicaltrials.gov) - Apr 28, 2016
P1/2, N=10, Not yet recruiting,
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
Trial primary completion date: Safety and Effect of SANGUINATE (clinicaltrials.gov) - Apr 18, 2016
P2, N=12, Recruiting,
Initiation date: Jan 2016 --> Jan 2015 Trial primary completion date: Dec 2015 --> May 2016
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
New P2 trial: A Study on SANGUINATE (clinicaltrials.gov) - Jan 19, 2016
P2, N=60, Not yet recruiting,
- |||||||||| Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
New P2 trial: SANGUINATE (clinicaltrials.gov) - Nov 9, 2015
P2, N=10, Not yet recruiting,
|
